echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Antitumor Therapy > Lung cancer! AstraZeneca Imfinzi (Infyfan) first-line treatment of wide-term small cell lung cancer (ES-SCLC) continues to significantly extend the total survival!

    Lung cancer! AstraZeneca Imfinzi (Infyfan) first-line treatment of wide-term small cell lung cancer (ES-SCLC) continues to significantly extend the total survival!

    • Last Update: 2020-06-06
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    May 31, 2020 /
    BiovalleyBIOON/---
    Astra
    Zeneca recently announced the results of the latest analysis of the CASPIAN trial in Phase III of Lung CancerThe data show that the anti-PD-L1 therapy Imfinzi (Infyfan, generic name: durvalumab, duvalliu monoantigen) combined standard care (SoC) with platinum chemotherapy (eposide etosides and cisplatin or caplatinum) first-line treatment of wide-term small cell lung cancer (ES-SCLC) adult patients has a sustained total clinical significance (OS) benefitCASPIAN is a random, open label, multi-center, global Phase III study that compares the efficacy and safety of patients with ES-SCLC in imfinzi-SoC-based platinum chemotherapy (eposide-sepolito-cisplatin or ca-platinum), Imfinzi-tremeliab-SoC-with-platinum chemotherapy, and SoC-based chemotherapy first-line treatment syllastAmong them, the Imfinzi-tremelimumab-SoC-containing platinum chemotherapy combination is a dual-immune checkpoint blocking combination chemotherapy program consisting of CTLA4 checkpoint inhibitor tremelimumab (an anti-CTLA4 monoantigen), PD-L1 checkpoint inhibitor Imfinzi (an anti-PD-L1 monoantigen) and SoC chemotherapyIn the study, Imfinzi was given a fixed dose (1500 mg), administered every three weeks, treated for 4 cycles, and patients in the experimental group received up to 4 cycles of SoC chemotherapy, while the control group allowed up to 6 cycles of SoC chemotherapy and preventive brain radiation therapy (PCI)The study was conducted in more than 200 clinical centers in 22 countries, including the United States, Europe, South America, Asia and the Middle EastThe primary endpoint is total lifetime (OS)In June 2019, the CASPIAN trial reached the main end point of OS: 27% reduction in the risk of death in the Imfinzi-SoC chemotherapy group compared to the SoC chemotherapy group (HR-0.73,95%CI: 0.591-0.909, p-0.0) 047), significant lying over the total lifetime (median OS: 13.0 months (11.5, 14.8) vs 10.3 months (9.3, 11.2), 18-month survival rate significantly increased (33.9% vs 24.7%)In addition, in all end-of-the-terms, the Imfinzi-SoC chemotherapy group showed therapeutic benefits compared to the SoC chemotherapy group, including a significant increase in progression survival rate (PFS rate: 17.5% vs 4.7%), an increase in the objective mitigation rate recognized at 12 months (ORR: 67.9% vs57.6%), and a 12-month remission (DOR) (DOR) (DOR: 3.6%)these figures make up theof the United StatesThe FDAapproved the foundation for first-line treatment of ES-SCLC adult patients with platinum chemotherapy (Eposide and cisplatin) in Imfinzi Joint Standard Care (SoC) in March 2020SCLC is an invasive, fast-growing cancer that, although initially responding to platinum-containing chemotherapy, can quickly recur and progressThis approval provides an important first-line treatment for ES-SCLC patientsCurrently, adult patients with ES-SCLC are also under regulatory review in the European Union and Japan for the first-line treatment of ES-SCLC chemotherapythe latest analysis, the data deadline is January 27, 2020The data showed that, after more than 2 years of median follow-up, the chemotherapy of Imfinzi-SoC showed a 25% reduction in the risk of sustained death compared to SoC chemotherapy (HR -0.75; 95% CI: 0.62-0.91; nominal p-0.0032)The updated median OS was 12.9 months and the SoC chemotherapy group was 10.5 monthsIn an after-the-fact analysis, the estimated 24-month survival rate was 22.2% in the Imfinzi-SoC chemotherapy group and 14.4% in the SoC chemotherapy groupAfter-the-fact analysis showed no progression survival rate for 24 months, with 11% in the Imfinzi-SoC chemotherapy group and 2.9% in the SoC chemotherapy groupin addition, the Imfinzi-SoC chemotherapy group maintained a high objective remission rate (ORR: 68% vs58%), and in the ex post analysis, the proportion of patients with a duration of 24 months was 13.5% in the Imfinzi-SoC chemotherapy group and 3.9% in the SoC chemotherapy groupAt 24 months, 12% of patients in the Imfinzi-SoC chemotherapy group continued to receive Imfinzi treatmentThe second experimental group in the CASPIAN trial,, assessed the addition of anti-CTLA4 mono-tremelimumab to the Imfinzi-SoC chemotherapy, showing os trends, but was not statistically significant compared to SoC chemotherapy In this trial, the safety and tolerance of Imfinzi combined chemotherapy were consistent with the known safety characteristics of these drugs "The latest results from the CASPIAN trial show that 22 percent of patients are still alive at 24 months of age, supporting the continuing benefits of Imfinzi-plus chemotherapy, an effective first-line solution for the treatment of widespread non-small cell lung cancer (ES-SCLC), said Dr Luis Paz Ares, chief investigator of the
    's OOCL, hospital in Otoub
    , Spain Improving the prognosis of ES-SCLC patients has always been a challenge, so few patients can survive for up to five years "After two years of median follow-up, Imfinzi continues to show sustained and meaningful survival improvement and long-lasting treatment response in patients with this devastating and invasive disease," said Jos? Baselga, executive vice president of oncology research and development at a AstraZeneca These data reinforce the new standard of care for patients with widespread small cell lung cancer (ES-SCLC) in Imfinzi-chemotherapy, and this program provides patients with a convenient dose every 4 weeks during maintenance We look forward to bringing the benefits of Imfinzi to patients around the world "
    lung cancer is the leading cause of cancer death in both men and women, accounting for about one-fifth of all cancer deaths Lung cancer is roughly divided into non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC), of which SCLC accounts for about 15% About two-thirds of SCLC patients are diagnosed with widespread disease, i.e the cancer has spread widely throughout the lungs or to other parts of the body SCLC is an aggressive, fast-growing cancer that, despite initial reactions to platinum-containing chemotherapy, relapses and progression strains quickly, with a particularly poor prognosis, with only 6% of SCLC patients surviving five years after diagnosis Imfinzi (Infyfan, Duvaliu monoantigen) is a humanized PD-L1 monoclonal antibody that blocks the binding of PD-L1 with PD-1 and CD80, thus blocking the immune escape of tumor
    and releasing the suppressed immune response To date, Imfinzi has been approved in more than 60 countries (including the United States, Japan, China, and the European Union as a whole) for treatment of non-reprecyibility of non-rectructive, stage III non-small cell lung cancer (NSCLC) patients who have not developed disease progressonomes after platinum-based chemotherapy synchrotron radiotherapy In addition, Imfinzi has been approved in more than 10 countries, including the United States, for advanced bladder cancer patients who have received chemotherapy containing platinum As part of a broader development of lung cancer, Imfinzi is also being tested in another Phase III clinical study, ADRIATIC, where the ACLC patients received simultaneous chemotherapy (CCRT) for simultaneous chemotherapy (CCRT), which is expected to be available in 2021 tremelimumab is a monoclonal antibody that targets cytotoxic T lymphocyte antigen 4 (CTLA-4), blocks the activity of CTLA-4, promotes T-cell activation, initiates tumor
    immune response, and promotes cancer cell death Tremelimumab and Persimmon Squibb have been targeted by the same target CTLA-4 for the antibody drug Yervoy (Ipitano) , AstraZeneca is currently conducting a large clinical project to evaluate The treatment of Imfinzi as a combination of single-drug therapy and combined tremelimab and its drugs for NSCLC, SCLC, bladder cancer, head and neck cancer, liver cancer
    , cervical cancer, bile duct cancer and other solid tumors (biovalleybioon.com) original origin: Imfinzi showed a lyf of the overall survival survival in 1st-line obed-stage small cell cell lung cancer in phase III CASPIAN trial
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.